Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Glioblastoma (GBM) presents significant therapeutic challenges due to tumor heterogeneity.
• Chimeric antigen receptor (CAR) T cell therapy shows promise but faces limitations in targeting GBM effectively.

Purpose of the Study:

• To develop a novel CAR T cell strategy for broader and more effective GBM targeting.
• To investigate the potential of chlorotoxin (CLTX) as a targeting domain for CAR T cells against GBM.

Main Methods:

• Engineered CAR T cells incorporating the GBM-binding peptide chlorotoxin (CLTX).
• Evaluated CLTX-CAR T cell binding affinity and specificity across diverse GBM tumors and cells.
• Assessed anti-GBM efficacy in orthotopic xenograft GBM models.
• Investigated the requirement of matrix metalloproteinase-2 (MMP-2) for CLTX-CAR T cell targeting.

Main Results:

• CLTX peptide demonstrated broad binding to a significant proportion of GBM tumors and their constituent cells.
• CLTX-CAR T cells exhibited potent anti-GBM activity, effectively targeting tumors with low expression of other GBM antigens.
• Tumor regression was observed in orthotopic xenograft GBM models following CLTX-CAR T cell treatment.
• CLTX-CAR T cell targeting was dependent on the cell surface expression of matrix metalloproteinase-2 (MMP-2).
• No significant off-target effector activity was observed in normal cells or in vivo.

Conclusions:

• The development of CLTX-CAR T cells represents a novel approach to overcome GBM tumor heterogeneity and antigen escape.
• This strategy expands the repertoire of CAR T cells for improved tumor-selective targeting in glioblastoma.
• Peptide toxins offer a viable alternative for CAR design, enhancing therapeutic potential against challenging cancers.